Pacira BioSciences Inc (FRA:82P) Stock Price, Trades & News

Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.

Financial Strength

5/10

Name	Current	Vs Industry
Cash-To-Debt	0.49
Equity-to-Asset	0.54
Debt-to-Equity	0.63
Debt-to-EBITDA	3.47
Interest Coverage	1.14
Piotroski F-Score	8/9	0 1 2 3 4 5 6 7 8 9
Altman Z-Score	1.96	Distress Grey Safe
Beneish M-Score	-2.81	Manipulator Not Manipulator
WACC vs ROIC		WACC ROIC

Growth Rank

8/10

	Name	Current	Vs Industry		Vs History
	3-Year Revenue Growth Rate	4
	3-Year EBITDA Growth Rate	-3.4
	3-Year EPS without NRI Growth Rate	0.8
	3-Year FCF Growth Rate	7
	Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank	20.36
	Future 3-5Y Total Revenue Growth Rate Estimate	8.54

Momentum Rank

2/10

	Name	Current	Vs Industry		Vs History
	5-Day RSI	69.4
	9-Day RSI	67.05
	14-Day RSI	63.97
	3-1 Month Momentum %	4.79
	6-1 Month Momentum %	-9.63
	12-1 Month Momentum %	0.51

Liquidity Ratio

	Name	Current	Vs Industry		Vs History
	Current Ratio	4.73
	Quick Ratio	3.35
	Cash Ratio	1.86
	Days Inventory	357.09
	Days Sales Outstanding	58.02
	Days Payable	48.14

Dividend & Buy Back

	Name	Current	Vs Industry		Vs History
	3-Year Average Share Buyback Ratio	3.6
	Shareholder Yield %	36.32

Profitability Rank

6/10

	Name	Current	Vs Industry		Vs History
	Gross Margin %	79.34
	Operating Margin %	2.18
	Net Margin %	0.7
	EBITDA Margin %	16.11
	FCF Margin %	17.99
	OCF Margin %	19.28
	ROE %	0.71
	ROA %	0.37
	ROIC %	0.64
	3-Year ROIIC %	14.44
	ROC (Joel Greenblatt) %	6.95
	ROCE %	2.29
	Years of Profitability over Past 10-Year	5
	Moat Score	4
	Tariff Resilience Score	8

GF Value Rank

10/10

	Name	Current	Vs Industry		Vs History
	PE Ratio	215.17
	Forward PE Ratio	8.73
	PE Ratio without NRI	11.91
	Shiller PE Ratio	191.09
	Price-to-Owner-Earnings	32.72
	PS Ratio	1.52
	PB Ratio	1.55
	Price-to-Tangible-Book	3.61
	Price-to-Free-Cash-Flow	8.44
	Price-to-Operating-Cash-Flow	7.88
	EV-to-EBIT	45.01
	EV-to-Forward-EBIT	26.57
	EV-to-EBITDA	10.35
	EV-to-Forward-EBITDA	9.5
	EV-to-Revenue	1.67
	EV-to-Forward-Revenue	1.6
	EV-to-FCF	9.23
	Price-to-GF-Value	0.87
	Price-to-Projected-FCF	0.59
	Price-to-Median-PS-Value	0.33
	Price-to-Graham-Number	1.38
	Earnings Yield (Greenblatt) %	2.22
	FCF Yield %	13.06
	Forward Rate of Return (Yacktman) %	-0.8

Financials (Next Earnings Date:2026-08-05 Est.)

Annual Quarterly TTM

FRA:82P's 30-Y Financials

AAPL

Income Statement Breakdown FY

Annual Quarterly

Not Enough Data

AAPL

Balance Sheet Breakdown

Annual Quarterly

Not Enough Data

AAPL

Cashflow Statement Breakdown

Annual Quarterly

Not Enough Data

Operating Revenue by Business Segment

Operating Revenue by Geographic Region

Historical Operating Revenue by Business Segment

Value % YoY

Historical Operating Revenue by Geographic Region

Value % YoY

See Details

5-Step DuPont Analysis as of

Annual Quarterly

Not Enough Data

Guru Trades

See Details

Insider Trades

See Details

Peter Lynch Chart

Y-axis scale:

Log Linear

Interactive Chart

Performance

Dividend

Log

Bar

Annualized Return %

Symbol	1 Week	1 Month	3 Months	6 Months	YTD	1 Year	3 Years	5 Years	10 Years

Total Annual Return %

Symbol	2026	2025	2024	2023	2022	2021	2020	2019	2018	2017

Pacira BioSciences Inc Executives

Details

GF Value™: €25.72

FRA:82P

Valuation Chart

Year:

Warning Signs

Warning! GuruFocus detected 2 Severe warning signs with 82P. Try a 7-Day Free Trial to check it out.

Analyst Estimate

Annual Quarterly

Key Statistics

	Name	Value
	Revenue (TTM) (Mil €)	631.521
	EPS (TTM) (€)	0.102
	Beta	-0.3536
	3-Year Sharpe Ratio	-0.17
	3-Year Sortino Ratio	-0.25
	Volatility %	42.45
	14-Day RSI	63.97
	14-Day ATR (€)	0.59266
	20-Day SMA (€)	20.48
	12-1 Month Momentum %	0.51
	52-Week Range (€)	15.4 - 23.4
	Shares Outstanding (Mil)	39.35

Piotroski F-Score Details

Year:

	Component	Result
	Piotroski F-Score	8
	Positive ROA
	Positive CFROA
	Higher ROA yoy
	CFROA > ROA
	Lower Leverage yoy
	Higher Current Ratio yoy
	Less Shares Outstanding yoy
	Higher Gross Margin yoy
	Higher Asset Turnover yoy

Pacira BioSciences Inc Filings

10-K10-QForm 4Others

	Filing Date	Document Date	Form
No Filing Data

Pacira BioSciences Inc Stock Events

Financials Calendars

Event	Date	Price (€)
Third quarter earnings conference call for 2026	2026-11-06 16:30	In 122 days
Third quarter earnings results for 2026	2026-11-06	In 121 days
Second quarter earnings conference call for 2026	2026-08-05 16:30	In 29 days
Second quarter earnings results for 2026	2026-08-05	In 28 days
General meeting for 2026	2026-06-09	19.50 (+0.00%)
Goldman Sachs 47th Annual Global Healthcare Conference	2026-06-08 13:20	19.70 (+3.14%)
Guidance call for 2026	2026-06-03 09:55	19.40 (-0.51%)
RBC Capital Markets Global Healthcare Conference	2026-05-20 08:30	19.20 (+0.00%)
First quarter earnings conference call for 2026	2026-04-30 16:30	21.20 (-1.85%)
First quarter earnings results for 2026	2026-04-30	21.20 (-1.85%)

Show

Entries

Pacira BioSciences Inc Frequently Asked Questions

What is Pacira BioSciences Inc(FRA:82P)'s stock price today?

The current price of FRA:82P is €22.40. The 52 week high of FRA:82P is €23.40 and 52 week low is €15.40.

When is next earnings date of Pacira BioSciences Inc(FRA:82P)?

The next earnings date of Pacira BioSciences Inc(FRA:82P) is 2026-08-05 Est..

Does Pacira BioSciences Inc(FRA:82P) pay dividends? If so, how much?

Pacira BioSciences Inc(FRA:82P) does not pay dividend.

Press Release

	Subject	Date
	Pacira BioSciences Announces Stockholders Have Elected All Three of the Company's Director Nominees at Annual Meeting	2026-06-09
	Pacira BioSciences Reminds Stockholders to Vote the BLUE Proxy Card "FOR" the Election of the Company's Highly Qualified Nominees Ahead of its Annual Meeting	2026-06-04
	Pacira BioSciences Highlights Leading Independent Proxy Advisory Firm ISS' Recommendation to Vote "FOR" All of Pacira's Director Nominees	2026-06-01
	DOMA PERPETUAL CAPITAL MANAGEMENT QUESTIONS WHY SHAREHOLDERS SHOULD VOTE TO CONTINUE WITH A BOARD THAT HAS OVERSEEN A DECADE OF VALUE DESTRUCTION	2026-05-28
	A LETTER TO PACIRA BIOSCIENCES SHAREHOLDERS FROM DOMA PERPETUAL CAPITAL MANAGEMENT LLC	2026-05-21
	DOMA Perpetual Director Nominees Send Letter to Shareholders of Pacira Biosciences	2026-05-20
	DOMA Perpetual Issues & Mails Letter to Shareholders of Pacira BioSciences - Along with its Definitive Proxy Statement & WHITE Proxy Card - Urging Shareholders to Vote "FOR" DOMA's Three Highly Qualif	2026-05-13
	DOMA Perpetual Nominates Three Highly Qualified Candidates for the Board of Pacira BioSciences, Inc.	2026-03-12
	DOMA Perpetual Nominates Three Highly Qualified Candidates for the Board of Pacira BioSciences, Inc.	2026-03-11
	DOMA Perpetual Capital Management Announces Intent to Nominate Three Highly Qualified, Independent Director Candidates at 2026 Annual Meeting of Pacira BioSciences, Inc.	2025-12-30

10/Page

Articles on Pacira BioSciences Inc

No articles.

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.